Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10 Leukemia 8 Leukemia, Myeloid, Chronic-Phase 6 Blast Crisis 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Sarcoma 4 Melanoma 4 Gastrointestinal Stromal Tumors 4 Leukemia, Myeloid, Accelerated Phase 3 Sarcoma, Synovial 2 Oligodendroglioma 2 Leukemia, Myeloid, Acute 2 Glioma 2 Colorectal Neoplasms 2 Central Nervous System Neoplasms 2 Brain Neoplasms 2 Astrocytoma 2 Uterine Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Endometrial Stromal 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma 1 Refractory Desmoplastic Small Round Cell Tumors 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Piebaldism 1 Ovarian Neoplasms 1 Neurofibrosarcoma 1 Neurofibromatoses 1

Interventions

Everolimus 2 carbon-11 acetate 1 Sirolimus 1 Simvastatin 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphangioleiomyomatosis × Imatinib Mesylate × Clear all

NCT03131999 2020-06-16

LAMP-1

Medical University of South Carolina

Phase 1/2 Completed

18 enrolled 7 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡